Next quarter’s earnings estimate for IGS1 is -€0.03 with a range of -€0.03 to -€0.03. The previous quarter’s EPS was -€0.02. IGS1 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 53.85% of the time in the same period. In the last calendar year IGS1 has Underperformed its overall industry.

IGS1 Sales Forecast

Next quarter’s sales forecast for IGS1 is €190.44K with a range of €190.44K to €190.44K. The previous quarter’s sales results were €392.31K. IGS1 beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.69% of the time in the same period. In the last calendar year IGS1 has Outperformed its overall industry.

Detailed List of Analyst Forecasts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Edward Woo

Ascendiant

€3.38→€3.62

Buy

939.73%

Upside

Reiterated

08/31/24

We are adjusting our FY25 estimates for revenue to $1.1 million, from $1.5 million, and for EPS to $(0.13) from $(0.12). Reported positive interim results: On March 20, IGC reported results of an interim analysis of its ongoing Phase 2 trial for IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (AAD). The interim data demonstrates a clinical and statistically significant reduction in agitation compared to placebo in patients with Alzheimer’s disease. This and additional positive data may allow the company to speed up its current clinical trials and FDA approval pathways.

James Molloy

Alliance Global Partners

€3.38

Buy

870.41%

Upside

Initiated

07/17/24

IGC Pharma initiated with a Buy at Alliance Global PartnersIGC Pharma initiated with a Buy at Alliance Global Partners

Best Analysts Covering IGC Pharma

Which Analyst Should I Follow If I Want to Buy DE:IGS1 and Sell After:

1 Month

xxx

Success Rate

2/3 ratings generated profit

Average Return

+1.93%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +1.93% per trade.

3 Months

xxx

Success Rate

2/3 ratings generated profit

Average Return

+19.60%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +19.60% per trade.

1 Year

Edward WooAscendiant

Success Rate

2/3 ratings generated profit

Average Return

+1.27%

reiterated a buy rating 4 months ago

Copying Edward Woo's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +1.27% per trade.

2 Years

xxx

Success Rate

2/3 ratings generated profit

Average Return

+1.27%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +1.27% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IGS1 Analyst Recommendation Trends

Rating

Feb 24

Jul 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IGS1 has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IGS1 average Analyst price target in the past 3 months is ―.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

IGS1 Stock Forecast FAQ

What is DE:IGS1’s average 12-month price target, according to analysts?

Currently, no data Available

What is DE:IGS1’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:IGS1, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IGC Pharma a Buy, Sell or Hold?

Currently, no data Available

What is IGC Pharma’s share price target?

Currently, no data Available

What do analysts say about IGC Pharma?

Not enough analysts have published a price target to provide an average price target.

How can I buy shares of IGC Pharma?

To buy shares of DE:IGS1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

IGC Pharma (IGS1) Stock Forecast & Price Target

IGS1 Analyst Ratings

IGS1 Stock 12 Month Forecast

IGS1 Financial Forecast

IGS1 Earnings Forecast

IGS1 Sales Forecast

Detailed List of Analyst Forecasts​

Best Analysts Covering IGC Pharma

IGS1 Analyst Recommendation Trends

IGS1 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts